subscribeSubscribe
U.S. FDA accepts supplemental New Drug Application for OFEV for children

U.S. FDA accepts supplemental New Drug Application for OFEV for children
PR NEWSWIRE
25 Jul 2023
Share Share
Lotus` Generic Nintedanib Esylate Receives Approval in the U.S.

Lotus` Generic Nintedanib Esylate Receives Approval in the U.S.
FDA
12 Jan 2023
Share Share
Lotus` Generic Nintedanib Receives Approval in the U.S.

Lotus` Generic Nintedanib Receives Approval in the U.S.
FDA
12 Jan 2023
Share Share
New data from Boehringer support the potential use of nintedanib

New data from Boehringer support the potential use of nintedanib
BUSINESSWIRE
05 Sep 2022
Share Share
NICE approves Ofev for PF-ILD

NICE approves Ofev for PF-ILD
Lucy Parsons PHARMATIMES
18 Oct 2021
Share Share
Blade shows +ve Data from Drug-Drug Interaction Study of Cudetaxesta in IPF

Blade shows +ve Data from Drug-Drug Interaction Study of Cudetaxesta in IPF
BUSINESSWIRE
20 Sep 2021
Share Share
SMC approves nintedanib for patients with chronic lung disease

SMC approves nintedanib for patients with chronic lung disease
PHARMAFILE
10 Jun 2021
Share Share
Study analysis available during ATS 2021 supports long-term treatment with Ofev®

Study analysis available during ATS 2021 supports long-term treatment with Ofev®
PRNEWSWIRE
14 May 2021
Share Share
OFEV® (nintedanib) receives positive recommendation from CADTH and INESSS

OFEV® (nintedanib) receives positive recommendation from CADTH and INESSS
NEWSWIRE
04 Mar 2021
Share Share
Boehringer and Icahn School begin enrolment in Covid-19 trial

Boehringer and Icahn School begin enrolment in Covid-19 trial
CLINICALTRIALSARENA
24 Nov 2020
Share Share